# 2026-08811: FDA Labels Germ DNA Stabilizer Device as Class II

2026-08811, Medical Devices; Immunology and Microbiology Devices; Classification of the Device To Preserve and Stabilize Relative Abundances of Microbial Nucleic Acids in Clinical Samples, is a Federal Register rule from Health and Human Services Department, Food and Drug Administration published 2026-05-06, effective 2026-05-06; PRIA reads it as touching household money (as of 2026-06-11).

- Canonical: https://policyrisk.com/federal-register/2026-08811
- As of: 2026-06-11
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-08811
- Title: Medical Devices; Immunology and Microbiology Devices; Classification of the Device To Preserve and Stabilize Relative Abundances of Microbial Nucleic Acids in Clinical Samples
- Type: Rule
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 24341
- Published: 2026-05-06
- Effective: 2026-05-06
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-06-11

## In one line

FDA Labels Germ DNA Stabilizer Device as Class II

## Summary

The FDA is officially putting a special label (Class II) on devices that keep tiny germs’ DNA stable in medical samples. This change makes sure these devices are safe and work well, while also making it easier and faster for new, helpful devices to reach patients. The new rules started May 6, 2026, and could save time and money for companies making these devices.

## Abstract

The Food and Drug Administration (FDA) is classifying the device to preserve and stabilize relative abundances of microbial nucleic acids in clinical samples into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the device to preserve and stabilize relative abundances of microbial nucleic acids in clinical samples. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.

## Effects PRIA read

- Device Reclassified to Class II: benefit, high. The FDA officially classed devices that preserve and stabilize microbial nucleic acids as Class II (special controls) effective May 6, 2026; the classification was applicable on November 3, 2021. Because this was done through the De Novo process, this device type can serve as a predicate for future…
- Easier Patient Access to Microbiome Tests: benefit, medium. The FDA says this Class II classification will enhance patients' access to beneficial innovative devices by reducing regulatory burdens. That means patients may see new devices for stabilizing microbial nucleic acids reach clinical use more quickly after May 6, 2026.
- 510(k) Premarket Notification Requirement: cost, medium. Devices of this type are subject to premarket notification under section 510(k) of the FD&C Act unless and until FDA exempts them. Sponsors must therefore prepare and submit a 510(k) to market these Class II devices.
- New Special Controls: Labeling and Studies: cost, medium. The rule sets special controls requiring specific labeling and validation studies: labels must list specimen types, device description, a warning that the device is not for detecting specific pathogens, and a warning to use only with legally marketed assays. Sponsors must also provide detailed desi…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-08811 on federalregister.gov](https://www.federalregister.gov/documents/2026/05/06/2026-08811/medical-devices-immunology-and-microbiology-devices-classification-of-the-device-to-preserve-and)
- [2026-08811 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-05-06/pdf/2026-08811.pdf)

## Related
- [Previous: 2026-08750, Extension of Postponement of Effectiveness for Certain Provisions of Trichloroe…](https://policyrisk.com/federal-register/2026-08750)
- [Next: 2026-08812, Medical Devices; Immunology and Microbiology Devices; Classification of the Cir…](https://policyrisk.com/federal-register/2026-08812)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-08811 (as of 2026-06-11).
